|
|
Study on the rule of traditional Chinese medicine in treating gastroesophageal reflux disease with syndrome of disharmony between liver and stomach |
XU Jingxin CHEN Hongci |
Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430065, China |
|
|
Abstract Objective To study the medication rule of traditional Chinese medicine in the treatment of gastroesophageal reflux disease with syndrome of disharmony between liver and stomach, and explore the ideas and theoretical basis of the application of high-frequency core prescription. Methods The clinical journal literatures collected from CNKI, Wanfang, VIP and CBM from January 2010 to December 2020 were taken as data source. “Traditional Chinese medicine inheritance computer system v3.0” was used for data mining, and association analysis and cluster analysis were conducted on the included prescriptions of Chinese medicine, so as to explore high-frequency drugs and usage rules of gastroesophageal reflux disease with syndrome of disharmony between liver and stomach. Results Among the 108 traditional Chinese medicine prescriptions finally included, most of the medicinal characters were “cold” and “warm”, meanwhile, the bitter and pungent were main medical taste. The frequently channel tropism of drugs was spleen, lung, stomach, liver. The function of the medicine was mainly regulating qi-flowing and tonifying, the most frequently used drug was Radix Bupleuri, Radix Paeoniae Alba, and Rhizoma Pinelliae. The high-frequency drug combinations were mainly Radix Glycyrrhizae-Radix Bupleuri, Radix Paeoniae Alba-Pericarpium Citri Reticulatae-Radix Bupleuri, Radix Glycyrrhizae-Rhizoma Cyperi-Radix Bupleuri, 20 core Chinese herbs and 3 groups of new drug-formulations were explored. Conclusion Facing with gastroesophageal reflux disease with syndrome of disharmony between liver and stomach, modern traditional Chinese medicine mostly uses “dispersing stagnated liver qi for regulating stomach, nourishing spleen and stomach” as the main therapeutic ideas, balancing cold and heat, and taking into account both deficiency and excess, so as to achieve the therapeutic effect of “balancing liver-qi and regulating stomach-qi”.
|
|
|
|
|
[1] 李海霞.胃食管反流病患者食管动力及酸反流相关因素的研究[D].武汉:华中科技大学,2008.
[2] 郭雪云,林连捷,王东旭,等.胃食管反流病诊断新进展——非侵入性唾液胃蛋白酶检测[J].胃肠病学和肝病学杂志,2017,26(9):1066-1070.
[3] Liu Y,Zhou PP,Zhang SX,et al. Association between gastroesophageal reflux disease and depression disorder:A protocol for systematic review and meta-analysis [J]. Medicine(Baltimore),2020,99(43):e22696.
[4] 毕红岩,王凤云,唐旭东.基于社会网络研究的134例胃食管反流病中医证候分析[J].中国中医药信息杂志,2015, 22(12):30-33.
[5] 阙任烨,沈艳婷,林柳兵,等.疏肝和胃方联合雷贝拉唑治疗肝胃不和型难治性反流性食管炎的临床疗效观察[J].中华中医药学刊,2017,35(8):1948-1953.
[6] 李军祥,陈誩,李岩.胃食管反流病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(3):221-226,232.
[7] 国家药典委员会.中华人民共和国药典[S].一部.北京:中国医药科技出版社,2020:72-108,257-258,293.
[8] 秦昌遇.症因脉治[M].北京:人民卫生出版社,2006:112.
[9] 秦伯未.临证备要[M].北京:人民卫生出版社,2005:101.
[10] 梁邦杰.胃食管反流病中医诊治规律探讨[D].南京:南京中医药大学,2012.
[11] 高鼓峰.医家心法[M].北京:人民卫生出版社,1983:77.
[12] 沈琳,何晓瑾.柴胡疏肝散临床新用三则[J].中西医结合心血管病电子杂志,2019,7(16):152-153,155.
[13] 李升标.半夏泻心汤加味治疗胃脘痛的经验小结[J].四川中医,2002,20(6):40-41.
[14] 贾涛,赵宁,赵振平.血管活性肠肽和一氧化氮在不同类型胃食管反流病中的表达及意义[J].新乡医学院学报,2015,32(10):943-946.
[15] 魏仕兵,来要良.辛开苦降法对非糜烂性胃食管反流病患者食管动力及酸反流的影响[J].环球中医药,2017, 10(10):1185-1189.
[16] 管华全,谭峰,李飞,等.胃食管反流病中医治疗经验小结[J].世界华人消化杂志,2016,24(12):1819-1823.
[17] 白改艳,李岩.幽门螺杆菌耐药性机制及中药治疗进展[J].中国中西医结合消化杂志,2020,28(6):477-481.
[18] 李合国,焦星.从肝胃论治胃食管反流病的临床体会[J].中医临床研究,2019,11(30):139-140.
[19] 李戈锐.胃食管反流病70例治疗分析[J].中外医疗,2011,30(2):91.
[20] 布立影.布明德老师治疗胃食管反流病的经验[J].河北中医,2016,38(2):165-167.
[21] 林家华.柴芍六君子汤合痛泻要方治疗腹泻型肠易激综合征(肝郁脾虚证)的临床观察[D].广州:广州中医药大学,2018.
[22] 许多,李书,李爽.胃食管反流病中医证型分布与焦虑抑郁关系的研究[J].中国医药导报,2019,16(17):27-30.
[23] 郑莹,王帅,孟宪生,等.中药枳壳挥发油成分气相色谱-质谱联用分析和促进胃肠动力药效研究[J].时珍国医国药,2015,26(3):516-518.
[24] 孙秀梅,时海燕,张兆旺,等.用均匀设计优选香附SFE-CO2萃取后药渣的半仿生法工艺条件[J].中国中药杂志,2009,34(22):2880-2883.
[25] 周瑞,项昌培,张晶晶,等.黄连化学成分及小檗碱药理作用研究进展[J].中国中药杂志,2020,45(19):4561-4573.
[26] 钟赣生.中药学[M].10版.北京:中国中医药出版社,2016:180-181,531-532,686-687.
[27] 郭冬梅.柴胡疏肝散治疗肝胃不和型胃食管反流病55例[J].中国中医药现代远程教育,2012,10(23):18-19. |
|
|
|